Skip to main content
. Author manuscript; available in PMC: 2019 Feb 24.
Published in final edited form as: Lancet Oncol. 2017 Mar 31;18(5):587–598. doi: 10.1016/S1470-2045(17)30239-5

Table 3:

Overview of safety

1 mg/kg (n=4) 3 mg/kg (n=13) 10 mg/kg (n=15) 20 mg/kg (n=21)
Any treatment-related adverse event 3 (75%) 9 (69%) 14 (93%) 17 (21%)
Grade ≥3 treatment-related adverse event 1 (25%) 0 5 (33%) 3 (14%)
Treatment-related adverse event leading to treatment discontinuation 1 (25%) 0 1 (7%) 4 (19%)
Serious treatment-related adverse event 0 0 3 (20%) 3 (14%)
Immune-related treatment-related adverse event 0 1 (8%) 2 (13%) 2 (10%)

Data are n (%).